Aurobindo Pharma Ltd’s consolidated net profit increased 2.8 per cent at ₹₹595 crore in the the third quarter ended December 31, 2017 against ₹578.6 crore in the corresponding quarter of the previous financial year. Revenue increased by 11 per cent at ₹4,336 crore (₹3,906 crore). During the quarter, the US Formulations sale had gone up by 9.4 per cent, while the same from Europe increased 37 per cent.
The board had approved second interim dividend at 100 pc, that is, ₹1 per equity share of ₹1 for the year FY17-18.